These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 7919374

  • 1. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.
    Carrie D, Caranobe C, Saivin S, Houin G, Petitou M, Lormeau JC, Van Boeckel C, Meuleman D, Boneu B.
    Blood; 1994 Oct 15; 84(8):2571-7. PubMed ID: 7919374
    [Abstract] [Full Text] [Related]

  • 2. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: an experimental study in two models of thrombosis in the rabbit.
    Amar J, Caranobe C, Sie P, Boneu B.
    Br J Haematol; 1990 Sep 15; 76(1):94-100. PubMed ID: 2223652
    [Abstract] [Full Text] [Related]

  • 3. A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit.
    Carrie D, Caranobe C, Boneu B.
    Br J Haematol; 1993 Apr 15; 83(4):622-6. PubMed ID: 8390849
    [Abstract] [Full Text] [Related]

  • 4. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.
    Meuleman DG, Hobbelen PM, Van Dinther TG, Vogel GM, Van Boeckel CA, Moelker HC.
    Semin Thromb Hemost; 1991 Apr 15; 17 Suppl 1():112-7. PubMed ID: 2068564
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological properties of CY 216 and of its ACLM and BCLM components in the rabbit.
    Peyrou V, Lormeau JC, Caranobe C, Gabaig AM, Crepon B, Saivin S, Houin G, Sié P, Boneu B.
    Thromb Haemost; 1994 Aug 15; 72(2):268-74. PubMed ID: 7831664
    [Abstract] [Full Text] [Related]

  • 6. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.
    Herbert JM, Hérault JP, Bernat A, van Amsterdam RG, Lormeau JC, Petitou M, van Boeckel C, Hoffmann P, Meuleman DG.
    Blood; 1998 Jun 01; 91(11):4197-205. PubMed ID: 9596667
    [Abstract] [Full Text] [Related]

  • 7. Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin.
    Herbert JM, Hérault JP, Bernat A, van Amsterdam RG, Vogel GM, Lormeau JC, Petitou M, Meuleman DG.
    Circ Res; 1996 Sep 01; 79(3):590-600. PubMed ID: 8781492
    [Abstract] [Full Text] [Related]

  • 8. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
    Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J.
    Thromb Res; 1987 Apr 15; 46(2):187-98. PubMed ID: 3603420
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats.
    Hobbelen PM, van Dinther TG, Vogel GM, van Boeckel CA, Moelker HC, Meuleman DG.
    Thromb Haemost; 1990 Apr 12; 63(2):265-70. PubMed ID: 2363127
    [Abstract] [Full Text] [Related]

  • 11. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ, Levi M, Nurmohamed MT, Büller HR, ten Cate JW.
    Thromb Haemost; 1994 Sep 12; 72(3):377-80. PubMed ID: 7855787
    [Abstract] [Full Text] [Related]

  • 12. Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity.
    Vogel GM, Meuleman DG, Van Dinther TG, Buijsman R, Princen AW, Smit MJ.
    J Thromb Haemost; 2003 Sep 12; 1(9):1945-54. PubMed ID: 12941035
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man.
    Boneu B, Necciari J, Cariou R, Sié P, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T.
    Thromb Haemost; 1995 Dec 12; 74(6):1468-73. PubMed ID: 8772222
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U, Ku P, Malinowski J, Zhu BY, Scarborough RM, Marlowe CK, Wong PW, Lin PH, Hollenbach SJ.
    Eur J Pharmacol; 2000 Apr 21; 395(1):51-9. PubMed ID: 10781674
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
    Diquélou A, Dupouy D, Cariou R, Sakariassen KS, Boneu B, Cadroy Y.
    Thromb Haemost; 1995 Nov 21; 74(5):1286-92. PubMed ID: 8607111
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP, Bernat A, Gaich C, Herbert M.
    Thromb Haemost; 2002 Feb 21; 87(2):238-44. PubMed ID: 11858483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.